Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 7/20 | 0.62 |
| ▸ | PSEN2 | P49810 | 7/20 | 0.62 |
| ▸ | APH1B | Q8WW43 | 7/20 | 0.62 |
| ▸ | NCSTN | Q92542 | 7/20 | 0.62 |
| ▸ | APH1A | Q96BI3 | 7/20 | 0.62 |
| ▸ | PSENEN | Q9NZ42 | 7/20 | 0.62 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL138071 | 0.90 | PSEN1 (0.65) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL139606 | 0.84 | PSEN1 (0.65) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL155495 | 0.83 | PSEN1 (0.88) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL137908 | 0.81 | PSEN1 (0.60) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL138912 | 0.81 | PSEN1 (0.62) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL138986 | 0.80 | PSEN1 (0.71) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL139391 | 0.79 | PSEN1 (0.60) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL139365 | 0.79 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL154824 | 0.78 | PSEN1 (0.89) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL139444 | 0.78 | PSEN1 (0.89) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822699-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822699-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-02 | — | — | US | disclosed |
| US-20120059030-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059030-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059030-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BACE1, BACE2, APP | PSEN1 5/4885PSEN2 8/4885APH1B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.